Stocks and Investing
Stocks and Investing
Tue, May 15, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, May 14, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, May 11, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gena Wang Upgraded (SRPT) to Buy on, May 11th, 2018
Gena Wang of Barclays, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Buy on, May 11th, 2018.
Gena has made no other calls on SRPT in the last 4 months.
There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 2 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Hartaj Singh of "Oppenheimer" Downgraded from Buy to Hold on, Friday, May 4th, 2018
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $91 on, Friday, May 4th, 2018
These are the ratings of the 4 analyists that currently disagree with Gena
- Alethia Young of "Credit Suisse" Maintained at Buy with Decreased Target to $92 on, Friday, May 4th, 2018
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $95 on, Wednesday, March 14th, 2018
- Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $92 on, Tuesday, March 13th, 2018
- Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $92 on, Monday, March 12th, 2018